(MedPage Today) — An investigational small-molecule, nonpeptide oral GLP-1 receptor agonist significantly reduced weight in adults with obesity in the randomized ATTAIN-1 trial.
At week 72, orforglipron at multiple doses proved superior to placebo…
Source link : https://www.medpagetoday.com/meetingcoverage/easd/117495
Author :
Publish date : 2025-09-16 22:01:00
Copyright for syndicated content belongs to the linked Source.
